RxDoctor Payments Data

James Pfeiff, MD

Undersea and Hyperbaric Medicine · Rome, NYNPI 1336225150

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 38 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by AbbVie at 38.7% of the total. Reporting peaked in 2022 at $263 and has fallen 82.7% since, to $46 in 2025.

$851in general payments, 2019–2025

Across 38 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$329
  • Smith+Nephew$154
  • Kerecis Limited$68
  • Hydrofera LLC$47
  • Solventum Corporation$39
  • Integra Lifesciences Corporation$33
  • plus $181 from 9 others

What the payments were for

  • Food & beverage$851100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few undersea and hyperbaric medicine providers in New Yorkto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$17,958
Medicare patients
50
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.19$17,463
Mupirocin84$673
Triamcinolone Acetonide33$258
Doxycycline Hyclate11$55
Levofloxacin18$45
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$154$17,46319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few undersea and hyperbaric medicine providers in New Yorkon file to place this against a meaningful peer group, so we don't.

Other undersea and hyperbaric medicine in Rome

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →